Rivaroxaban Inappropriate Dosage Predictor Factors Using The Ckd-Epi Equation

Autor: Perez Cabeza A, Gorriz J, Bravo Marques R, Chinchurreta Capote P, Lopez Tejero S, Gonzalez Correa J, Mesa Prado F, Valle Alberca A, Ruiz Mateas F

Publikováno v: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::f508193fcb3432fe71c570f6d43ea8c8
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4739

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice.

Autor: Pérez Cabeza AI; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., González Correa JA; Faculty of Health Sciences, University of Málaga, Málaga, Spain., Chinchurreta Capote PA; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Bravo Marqués R; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Ruiz Mateas F; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Rosas Cervantes G; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Mesa Prado F; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., López Tejero S; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Valle Alberca A; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain.

Publikováno v: Future cardiology [Future Cardiol] 2018 May; Vol. 14 (3s), pp. 9-16.